Literature DB >> 15552966

Superior mediastinal and neck lymphatic mapping in mid- and lower-thoracic esophageal cancer as defined by ferumoxides-enhanced magnetic resonance imaging.

Hiroshi Imano1, Satoru Motoyama, Reijiro Saito, Yoshihiro Minamiya, Yoshihisa Katayose, Manabu Okuyama, Masakatsu Nakamura, Koichi Ishiyama, Ryuji Sashi, Jun-ichi Ogawa.   

Abstract

OBJECTIVE: The purpose of this study was to detect lymphatic drainage into the superior mediastinum and neck in thoracic esophageal cancer patients using ferumoxides-enhanced magnetic resonance imaging (MRI), and to have this information assist in determining the appropriate extent of lymphadenectomy.
METHODS: Nine male patients with T2-T3 mid- and lower-thoracic esophageal cancer with lymph node metastasis were examined. The day before surgery, ferumoxides was endoscopically injected into the submucosal layer of the peritumoral lesion. Thereafter, lymph nodes in the superior mediastinum and neck, which were shown to be ferumoxides-enhanced on MRI, were harvested and evaluated; magnetic force from all harvested lymph nodes was measured ex vivo.
RESULTS: MRI of the superior mediastinum and neck revealed 1(median) ferumoxides-enhanced lymph nodes in eight (89%) patients, and there was laterality in the lymphatic mapping in both areas. Of the 15 lymph nodes into which drainage was detected by enhanced MRI, 12 (80%) were magnetite-positive. In six patients (67%), magnetic resonance enhanced lymph nodes corresponded completely with the ex vivo magnetite examination, and in 3 patients (33%) there was partial agreement. In 3 (60%) of the 5 patients that showed paratracheal and/or supraclavicular lymph node metastases, all of the affected nodes were detected by MRI; in one patient some of the affected nodes were detected.
CONCLUSION: Ferumoxides-enhanced MRI is useful for visualizing lymphatic drainage to the superior mediastinum and neck in thoracic esophageal cancer. It is an adequate procedure to form an estimate on the appropriate extent of lymphadenectomy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15552966     DOI: 10.1007/s11748-004-0137-5

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  17 in total

1.  Should en bloc esophagectomy be the standard of care for esophageal carcinoma?

Authors:  N Altorki; D Skinner
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

2.  Laparoscopic detection of sentinel lymph nodes in gastrointestinal cancer: a novel and minimally invasive approach.

Authors:  Y Kitagawa; M Ohgami; H Fujii; M Mukai; T Kubota; N Ando; M Watanabe; Y Otani; S Ozawa; H Hasegawa; T Furukawa; J Matsuda; K Kumai; T Ikeda; A Kubo; M Kitajima
Journal:  Ann Surg Oncol       Date:  2001-10       Impact factor: 5.344

3.  Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial.

Authors:  M Goldminc; G Maddern; E Le Prise; B Meunier; J P Campion; B Launois
Journal:  Br J Surg       Date:  1993-03       Impact factor: 6.939

4.  The role of the sentinel lymph node in gastrointestinal cancer.

Authors:  Y Kitagawa; H Fujii; M Mukai; T Kubota; N Ando; M Watanabe; M Ohgami; Y Otani; S Ozawa; H Hasegawa; T Furukawa; K Kumai; T Ikeda; T Nakahara; A Kubo; M Kitajima
Journal:  Surg Clin North Am       Date:  2000-12       Impact factor: 2.741

5.  A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus.

Authors:  T Nishihira; K Hirayama; S Mori
Journal:  Am J Surg       Date:  1998-01       Impact factor: 2.565

6.  Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy.

Authors:  R C Karl; R Schreiber; D Boulware; S Baker; D Coppola
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

7.  Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system.

Authors:  S Saini; D D Stark; P F Hahn; J Wittenberg; T J Brady; J T Ferrucci
Journal:  Radiology       Date:  1987-01       Impact factor: 11.105

8.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Outcomes of active operation during intensive followup for second primary malignancy after esophagectomy for thoracic squamous cell esophageal carcinoma.

Authors:  Satoru Motoyama; Reijiro Saito; Michihiko Kitamura; Jun-ichi Ogawa
Journal:  J Am Coll Surg       Date:  2003-12       Impact factor: 6.113

10.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy.

Authors:  H Fujita; T Kakegawa; H Yamana; I Shima; Y Toh; Y Tomita; T Fujii; K Yamasaki; K Higaki; T Noake
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

View more
  3 in total

1.  Estimating the need for neck lymphadenectomy in submucosal esophageal cancer using superparamagnetic iron oxide-enhanced magnetic resonance imaging: clinical validation study.

Authors:  Satoru Motoyama; Koichi Ishiyama; Kiyotomi Maruyama; Komei Narita; Yoshihiro Minamiya; Jun-Ichi Ogawa
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

2.  Status of involved lymph nodes and direction of metastatic lymphatic flow between submucosal and t2-4 thoracic squamous cell esophageal cancers.

Authors:  Satoru Motoyama; Kiyotomi Maruyama; Yusuke Sato; Shuetsu Usami; Toshinobu Nakatsu; Hajime Saito; Yoshihiro Minamiya; Jun-Ichi Ogawa
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

3.  Sentinel node biopsy during thoracolaparoscopic esophagectomy for advanced esophageal cancer.

Authors:  Judith Boone; Monique G G Hobbelink; Marguerite E I Schipper; Frank P Vleggaar; Inne H M Borel Rinkes; Robbert J de Haas; Jelle P Ruurda; Richard van Hillegersberg
Journal:  World J Surg Oncol       Date:  2016-04-19       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.